Balchem Corporation BCPC R2K
Company Overview
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.
Why Investors Should Care
Net profit has compounded at 11.6% per year over the last five years.
Revenue has grown at a 10.2% CAGR over the past five years.
Operating margin of 20.9% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.14.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $1.04B (+8.8% YoY); net profit $154.84M.
- Trailing 12 Months Year-on-year growth — revenue +8.1%, earnings +10.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.2%, profit CAGR 11.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.19% |
| 1 Year: | 8.10% |
Compounded Profit Growth
| 5 Years: | 11.59% |
| 1 Year: | 10.60% |
Stock Price Performance
| 1 Year: | +1.76% |
| 6 Months: | +0.37% |
| 3 Months: | -8.87% |
| 1 Month: | -2.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.47 · Neutral
P/E of 33.03 is above the sector median of 22.91 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.2% over 5 years.
- Profit CAGR of 11.6% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Basic Materials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BCPC Balchem Corporation R2K | 160.86 | 33.03 | $5.17B | 0.58% | 13.86% | 12.68% | 10.19% | 11.59% |
| 2 | LIN Linde plc NDXSPX | 522.54 | 34.65 | $241.59B | 1.22% | 12.46% | 18.23% | 13.90% | 18.47% |
| 3 | NEM Newmont Corporation SPX | 94.75 | 12.29 | $101.15B | 1.04% | - | 25.83% | 6.53% | 20.15% |
| 4 | FCX Freeport-McMoRan Inc. SPX | 61.95 | 32.78 | $89.06B | 0.88% | 12.50% | 15.63% | 1.35% | -1.26% |
| 5 | SHW The Sherwin-Williams Company SPX | 328.50 | 31.56 | $81.02B | 1.01% | 21.93% | 60.72% | 6.18% | 8.26% |
| 6 | ECL Ecolab Inc. SPX | 269.75 | 36.55 | $75.92B | 1.10% | 14.29% | 22.43% | 6.17% | 9.18% |
| 7 | CRH CRH plc SPX | 103.91 | 19.28 | $69.43B | 1.47% | 10.97% | 15.81% | 6.41% | 9.30% |
| 8 | APD Air Products and Chemicals, Inc. SPX | 299.40 | 31.55 | $66.67B | 2.57% | -0.62% | 12.35% | -1.77% | -39.16% |
| 9 | CTVA Corteva, Inc. SPX | 84.91 | 45.90 | $56.79B | 0.95% | - | 5.14% | 2.86% | 9.94% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 137.73M | 147.08M | 150.72M | 159.26M | 161.41M | 163.69M | 155.04M | 163.54M | 157.03M | 161.55M | 158.59M | 166.53M | 174.44M | 173.35M | 175.14M | 180.71M | 185.66M | 202.37M | 197.87M | 213.13M | 228.87M | 236.69M | 244.27M | 232.53M | 232.54M | 231.25M | 229.95M | 228.70M | 239.66M | 234.08M | 239.94M | 240.00M | 250.52M | 255.47M | 267.56M | 263.62M | 270.71M |
| Gross Profit | 46.45M | 44.66M | 46.93M | 44.43M | 46.76M | 46.18M | 51.64M | 51.46M | 53.47M | 48.00M | 51.33M | 49.09M | 53.92M | 54.01M | 54.35M | 55.33M | 55.38M | 56.37M | 56.82M | 58.73M | 59.45M | 60.93M | 64.07M | 71.51M | 71.88M | 68.43M | 68.64M | 73.17M | 77.35M | 76.54M | 74.99M | 81.51M | 82.99M | 85.36M | 86.34M | 88.17M | 93.11M | 95.45M | 93.90M | 101.08M |
| Operating Income | 23.33M | 22.95M | - | 22.70M | 24.83M | 23.05M | - | 27.24M | 27.10M | 25.52M | - | 26.48M | 26.40M | 26.03M | - | 26.28M | 26.92M | 29.03M | - | 30.57M | 30.59M | 32.51M | - | 38.34M | 39.92M | 33.62M | - | 34.41M | 42.84M | 43.61M | - | 41.68M | 45.80M | 47.99M | - | 51.02M | 51.44M | 54.58M | - | 55.63M |
| Net Income | 14.15M | 14.01M | 15.92M | 15.52M | 16.54M | 16.04M | 41.98M | 19.35M | 19.68M | 19.21M | 20.33M | 18.78M | 19.83M | 20.68M | 20.38M | 19.77M | 21.12M | 21.57M | 22.16M | 23.41M | 22.73M | 25.01M | 24.95M | 28.93M | 29.78M | 25.25M | 21.41M | 22.71M | 30.11M | 29.07M | 26.65M | 28.99M | 32.07M | 33.84M | 33.58M | 37.05M | 38.28M | 40.29M | 39.23M | 40.28M |
| Diluted EPS | 0.44 | 0.44 | 0.50 | 0.48 | 0.51 | 0.50 | 1.30 | 0.60 | 0.61 | 0.59 | 0.63 | 0.58 | 0.61 | 0.64 | 0.63 | 0.61 | 0.65 | 0.66 | 0.68 | 0.72 | 0.70 | 0.77 | 0.76 | 0.89 | 0.92 | 0.78 | 0.66 | 0.70 | 0.93 | 0.90 | 0.82 | 0.89 | 0.98 | 1.03 | 1.03 | 1.13 | 1.17 | 1.24 | 1.21 | 1.25 |
| R&D Expense | 1.92M | 1.68M | - | 1.81M | 2.28M | 2.71M | - | 2.57M | 3.23M | 2.54M | - | 2.90M | 2.85M | 2.70M | - | 2.70M | 2.57M | 2.69M | - | 2.75M | 2.90M | 3.16M | - | 3.23M | 2.92M | 3.00M | - | 3.45M | 3.79M | 3.87M | - | 4.10M | 3.85M | 4.33M | - | 4.66M | 4.30M | 4.50M | - | 5.88M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 219.44M | 255.07M | 291.87M | 310.39M | 337.17M | 541.38M | 552.49M | 553.20M | 594.79M | 643.68M | 643.71M | 703.64M | 799.02M | 942.36M | 922.44M | 953.68M | 1.04B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 661.91M | 620.38M | 617.48M | 666.53M |
| Gross Profit | 66.96M | 78.04M | 86.00M | 89.54M | 97.42M | 144.17M | 168.10M | 180.86M | 189.01M | 204.25M | 211.37M | 223.90M | 243.17M | 280.45M | 302.06M | 336.21M | 370.63M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 135.26M | 142.86M | 153.30M | 161.31M |
| Operating Income | 40.66M | 49.77M | 56.23M | 59.78M | 65.60M | 82.14M | 93.96M | 90.84M | 96.90M | 107.10M | 102.55M | 111.15M | 127.50M | 145.19M | 159.19M | 182.91M | 209.33M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 195.87M | 214.81M | 230.95M | 254.94M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.27M | 22.61M | 16.53M | 10.22M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 133.75M | 137.26M | 166.45M | 199.03M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.38M | 28.72M | 37.98M | 44.19M |
| Net Income | 26.79M | 33.28M | 38.77M | 40.01M | 44.87M | 52.83M | 59.72M | 55.97M | 90.07M | 78.57M | 79.67M | 84.62M | 96.10M | 105.37M | 108.54M | 128.47M | 154.84M |
| Diluted EPS | 0.93 | 1.12 | 1.28 | 1.32 | 1.45 | 1.69 | 1.89 | 1.75 | 2.79 | 2.42 | 2.45 | 2.60 | 2.94 | 3.25 | 3.35 | 3.93 | 4.75 |
| R&D Expense | 3.30M | 3.19M | 2.89M | 3.42M | 3.62M | 4.81M | 5.99M | 7.33M | 9.30M | 11.59M | 11.38M | 10.33M | 13.52M | 12.19M | 15.05M | 16.79M | 18.51M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 187.81M | 228.62M | 271.72M | 312.55M | 376.87M | 861.53M | 879.69M | 948.63M | 963.64M | 981.36M | 1.16B | 1.17B | 1.20B | 1.62B | 1.60B | 1.58B | 1.69B |
| Total Equity | 114.51M | 147.14M | 187.47M | 232.01M | 273.01M | 331.36M | 391.90M | 463.70M | 521.03M | 616.88M | 691.62M | 743.67M | 828.23M | 877.01M | 938.28M | 1.05B | 1.15B | 1.26B |
| Cash & Equivalents | 3.42M | 46.43M | 77.25M | 114.78M | 144.74M | 208.75M | 50.29M | 84.80M | 38.64M | 40.42M | 54.27M | 65.67M | 84.57M | 103.24M | 66.56M | 64.45M | 49.52M | 74.57M |
| Long Term Debt | - | - | 3.43M | 23.00K | 0 | 0 | 297.50M | 260.96M | 226.49M | 0 | 156.00M | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 41.16M | 39.71M | 39.53M | 45.51M | 469.63M | 415.98M | 427.59M | 346.75M | 289.74M | 412.01M | 337.61M | 322.31M | 686.23M | 543.23M | 425.46M | 428.84M |
| Current Liabilities | - | - | 29.51M | 30.91M | 30.23M | 35.75M | 95.52M | 81.12M | 101.01M | 108.40M | 82.06M | 92.26M | 94.43M | 143.80M | 140.04M | 148.49M | 157.69M | 176.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 48.07M | 39.03M | 44.90M | 53.78M | 55.69M | - | 103.83M | 107.61M | 110.62M | 118.70M | 124.46M | 150.49M | - | 138.54M | 183.76M | 182.00M | 216.56M |
| Investing Cash Flow | -3.64M | -11.05M | -6.61M | -14.00M | -8.38M | - | -42.28M | -133.59M | -42.70M | -31.99M | -156.22M | -34.59M | - | -416.01M | -34.81M | -59.74M | -43.89M |
| Financing Cash Flow | -1.53M | 3.18M | -632.00K | -9.84M | 16.46M | - | -25.84M | -19.45M | -68.63M | -71.45M | 43.38M | -101.16M | - | 246.68M | -153.32M | -133.81M | -152.81M |
| Capital Expenditure | -3.43M | -7.56M | -6.61M | -13.88M | -8.19M | -13.20M | -41.30M | -23.03M | -27.53M | -19.17M | -25.79M | -32.08M | - | -49.95M | -37.89M | -35.66M | -43.49M |
| Free Cash Flow | 44.64M | 31.47M | 38.29M | 39.90M | 47.51M | - | 62.53M | 84.58M | 83.09M | 99.53M | 98.67M | 118.41M | - | 88.59M | 145.87M | 146.34M | 173.07M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.80M | -4.37M | -11.55M | 19.86M |
| Share Buybacks | 0 | 937.00K | 109.00K | 1.70M | 1.93M | 1.07M | 1.21M | 1.59M | 1.91M | 1.39M | 21.32M | 13.46M | 35.24M | 35.42M | 4.47M | 5.68M | 107.64M |
| Dividends Paid | 2.01M | 3.09M | 4.31M | 11.70M | 0 | 7.86M | 9.25M | 10.72M | 12.07M | 13.43M | 15.13M | 16.70M | 18.72M | 20.71M | 22.87M | 25.58M | 28.29M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 30.5% | 30.6% | 29.5% | 28.8% | 28.9% | 26.6% | 30.4% | 32.7% | 31.8% | 31.7% | 32.8% | 31.8% | 30.4% | 29.8% | 32.7% | 35.3% | 35.7% |
| Operating Margin % | 18.5% | 19.5% | 19.3% | 19.3% | 19.5% | 15.2% | 17.0% | 16.4% | 16.3% | 16.6% | 15.9% | 15.8% | 16.0% | 15.4% | 17.3% | 19.2% | 20.2% |
| Net Margin % | 12.2% | 13.0% | 13.3% | 12.9% | 13.3% | 9.8% | 10.8% | 10.1% | 15.1% | 12.2% | 12.4% | 12.0% | 12.0% | 11.2% | 11.8% | 13.5% | 14.9% |
| ROE % | 18.2% | 17.8% | 16.7% | 14.7% | 13.5% | 13.5% | 12.9% | 10.7% | 14.6% | 11.4% | 10.7% | 10.2% | 11.0% | 11.2% | 10.3% | 11.2% | 12.3% |
| ROCE % | - | 25.0% | 23.3% | 21.2% | 19.2% | 10.7% | 11.8% | 10.7% | 11.3% | 11.9% | 9.6% | 10.4% | 12.1% | 9.8% | 11.0% | 12.9% | 13.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 15.07% | 4.84M | $807.46M |
| 2 | Vanguard Portfolio Management LLC | 6.83% | 2.19M | $365.81M |
| 3 | Vanguard Capital Management LLC | 4.46% | 1.43M | $238.84M |
| 4 | Wasatch Advisors LP | 4.43% | 1.42M | $237.39M |
| 5 | Conestoga Capital Advisors, LLC | 3.89% | 1.25M | $208.67M |
| 6 | State Street Corporation | 3.86% | 1.24M | $206.92M |
| 7 | Geode Capital Management, LLC | 3.26% | 1.05M | $174.65M |
| 8 | Morgan Stanley | 2.67% | 857.37K | $142.99M |
| 9 | Geneva Capital Management LLC | 2.63% | 846.50K | $141.17M |
| 10 | FMR, LLC | 1.86% | 598.67K | $99.84M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BCPC
Balchem Corporation to Participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026
MONTVALE, N.J., June 26, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the CJS Securities 26th Annual New Ideas S…
Balchem Corporation to Participate in the Wells Fargo Industrials Conference on June 10, 2026
MONTVALE, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- Balchem Corporation (NASDAQ: BCPC), a global specialty ingredient manufacturer for health and nutrition markets, announced they will participate in the Wells Fargo Industrials Conference on J…
Are Options Traders Betting on a Big Move in Balchem Stock?
Investors need to pay close attention to BCPC stock based on the movements in the options market lately.
Should Balchem’s Q1 2026 Earnings Jump and Buyback Activity Require Action From Balchem (BCPC) Investors?
In the first quarter of 2026, Balchem Corporation reported higher sales of US$270.71 million and net income of US$40.29 million year over year, while also completing a share repurchase of 159,539 shares for US$25.85 million under its Decemb…
Investment Firm Sells $12.2 Million Worth of Materials Stock, According to Latest SEC Filing
Trex Company is a leading provider of composite decking and outdoor living products for residential and commercial markets.
Here’s Why Investors Favored Balchem Corp. (BCPC)
Conestoga Capital Advisors, an asset management company, released its first-quarter 2026 investor letter. A copy of the letter is available to download here. The first quarter of 2026 started with optimism about the domestic economy and att…
BCPC — Frequently Asked Questions
What is the current share price of Balchem Corporation (BCPC)?
As of 2026-07-14 21:23 PDT, Balchem Corporation (BCPC) trades at $160.86 on NasdaqGS. Its 52-week range is $139.44 to $183.26.
What is the market capitalisation of BCPC?
Balchem Corporation (BCPC) has a market capitalisation of $5.17B on NasdaqGS.
What is the P/E ratio of BCPC?
BCPC trades at a trailing price-to-earnings (P/E) ratio of 33.03. The industry average P/E is 22.91. Its price-to-book (P/B) ratio is 4.13.
Does BCPC pay a dividend?
Balchem Corporation (BCPC) currently offers a dividend yield of 0.58%.
What is the return on equity (ROE) of BCPC?
BCPC has a return on equity (ROE) of 12.68%. Its return on capital employed (ROCE) is 13.86%.
Is BCPC a good stock to buy?
This page provides a data-driven analysis of Balchem Corporation (BCPC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.